Our Portfolio
We work on the best targets for patients
We have an exciting pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes – Solute Carriers, GPCRs, Inflammasome – with a focus on immunological and orphan diseases. We select targets with low translation risk through genetic association, pathway linked patient selection or immune signature stratification.

Click Target For More Info

Target Indication Discovery Preclinical Phase 1
MC2Orphan endocrine disorders
SLC15A4Lupus and other IFN-opathies
GPR65Inflammatory bowel disease
GasderminBroad immunology
cGASBroad immunology
Insurmountable ACTH antagonism for a best-in-class profile in rare endocrine disorders.
First-in-class solute carrier inhibitor against a highly validated target in Lupus and other IFN-opathies
First-in-class molecules driving novel anti-inflammatory biology in Inflammatory Bowel Disease.
First-in-class Gasdermin D inhibitors – a pipeline in a product.
Best-in-class cGAS inhibitor


Need more information about our pipeline?

Contact Us